Stephen Pinkerton Purchases 520,000 Shares of hVIVO (LON:HVO) Stock

hVIVO plc (LON:HVO) insider Stephen Pinkerton acquired 520,000 shares of the firm’s stock in a transaction on Monday, December 15th. The shares were bought at an average price of GBX 6 per share, for a total transaction of £31,200.

hVIVO Trading Up 27.0%

Shares of hVIVO stock traded up GBX 1.45 on Monday, reaching GBX 6.80. The company had a trading volume of 22,626,840 shares, compared to its average volume of 3,340,329. The firm has a market cap of £46.70 million, a price-to-earnings ratio of 8.82 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The firm’s 50-day moving average price is GBX 6.26 and its two-hundred day moving average price is GBX 8.75. hVIVO plc has a 1 year low of GBX 4.31 and a 1 year high of GBX 22.

hVIVO (LON:HVO) last posted its quarterly earnings data on Tuesday, September 23rd. The company reported GBX (0.29) EPS for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. As a group, research analysts predict that hVIVO plc will post 1.5492958 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HVO. Peel Hunt reiterated an “add” rating and set a GBX 10 target price on shares of hVIVO in a research report on Thursday, November 20th. Shore Capital decreased their price objective on hVIVO from GBX 35 to GBX 25 and set a “buy” rating for the company in a research note on Tuesday, September 23rd. Two equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of GBX 17.50.

About hVIVO

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.